N-Glycomic Profiling of Microsatellite Unstable Colorectal Cancer
Preprint
- 14 June 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Aberrant glycosylation affects cancer progression and immune evasion. Approximately 15% of colorectal cancers (CRCs) demonstrate microsatellite instability (MSI) and display major differences in outcomes and therapeutic responses as compared to corresponding microsatellite stable (MSS) tumors. We compared the N-glycan profiles of stage II and IV MSI CRC tumors, further subdivided into BRAFV600E wild-type and mutated subgroups (n=10 in each subgroup), with each other and with those of paired non-neoplastic mucosal samples using mass spectrometry. Further, the N-glycans of BRAFV600E wild-type stage II MSI tumors were compared to corresponding MSS tumors (n=9). Multiple differences in N-glycan profiles were identified between MSI CRCs and control tissues, as well as between stage II MSI and MSS samples. MSI CRC tumors showed a lower relative abundance of high-mannose N-glycans than the control tissues or the MSS CRCs. Among MSI CRC subgroups, acidic N-glycans showed tumor stage and BRAF mutation status dependent variation. Especially large, sulfated/phosphorylated, and putative terminal N-acetylhexosamine containing acidic N-glycans differed between the MSI CRC subgroups, showing opposite changes in stage II and IV, when comparing BRAF mutated and wild-type tumors. Our results show that molecular subgroups of CRC have characteristic glycan profiles that may explain certain carcinogenic properties of MSI tumors.Keywords
All Related Versions
- Version 1, 2023-06-14, Preprints
- Published version: Cancers, 15 (14), 3571.
This publication has 53 references indexed in Scilit:
- Association between mutational subgroups, Warburg‐subtypes, and survival in patients with colorectal cancerCancer Medicine, 2022
- Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancerVirchows Archiv, 2021
- JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusionsAnnals of Oncology, 2020
- Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?Cancer Cell, 2019
- The Association Between Mutations in BRAF and Colorectal Cancer–Specific Survival Depends on Microsatellite Status and Tumor StageClinical Gastroenterology and Hepatology, 2019
- BRAF mutation in sporadic colorectal cancer and Lynch syndromeVirchows Archiv, 2013
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancerCancer, 2011
- Determination of Carbohydrate‐Binding Preferences of Human Galectins with Carbohydrate MicroarraysChemBioChem, 2010
- Potential tumor markers for human gastric cancer: an elevation of glycan:sulfotransferases and a concomitant loss of α1,2-fucosyltransferase activitiesJournal of Cancer Research and Clinical Oncology, 2007
- Upregulation of galectins‐1 and ‐3 in human colon cancer and their role in regulating cell migrationInternational Journal of Cancer, 2002